ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment

Provencio Mariano; Serna-Blasco Roberto; Franco Fabio; Calvo Virgina; Royuela Ana; Auglytė Milda; Sánchez-Hernández Alfredo; de Julián Campayo María; García-Girón Carlos; Dómine Manuel; Blasco Ana; Sánchez José M.; Oramas Juana; Bosch-Barrera Joaquim; Sala María Á.; Sereno María; Ortega Ana L.; Chara Luis; Hernández Berta; Padilla Airam; Coves Juan; Blanco Remedios; Balsalobre José; Mielgo Xabier; Bueno Coralia; Jantus-Lewintre Eloisa; Molina-Vila Miguel Á.; Romero Atocha
European Journal of Cancer2021DOI: 10.1016/J.EJCA.2021.02.031
8阅读
引用收藏
分享

摘要

Background Survival data support the use of first-line osimertinib as the standard of care for epidermal growth factor receptor ( EGFR )–positive non-small cell lung cancer (NSCLC). However, it remains unclear whether upfront osimertinib is superior to sequential first- or second-generation tyrosine kinase inhibitors (TKIs) followed by osimertinib for all patients. It is impossible to predict which patients are at high risk of progression, and this constitutes a major limitation of the sequential TKI approach.;Patients and methods A total of 830 plasma samples from 228 patients with stage IV, EGFR -positive NSCLC who were treated with first-line TKIs were analysed by digital polymerase chain reaction (dPCR).;Results The circulating tumour DNA (ctDNA) levels helped to identify patients with significantly improved survival rate, regardless of the treatment. Patients treated with first- or second-generation TKIs (N = 189) with EGFR mutations in plasma at a mutant allele frequency (MAF) <7% before treatment initiation (low-risk patients) or who were ctDNA negative after 3 or 6 months of treatment and with an MAF <7% at diagnosis (high responders) had two-thirds lower risk of death than patients in the opposite situation (adjusted hazard ratio [HR] = 0.38; 95% confidence interval [CI]: 0.23–0.64 and HR = 0.22; 95% CI: 0.12–0.42, respectively). The median overall survival (OS) for low-risk patients and high responders treated with first- or second-generation TKIs was 34.2 months and not reached, respectively, regardless of second-line treatment. There were no significant difference in OS between low-risk or high-responder patients treated upfront with osimertinib (N = 39) and those treated under a sequential approach with osimertinib (N = 60). Median OS was not reached in both cases.;Conclusions Pre-treatment ctDNA levels identify low-risk patients, who may benefit from sequential TKI treatment. Information regarding EGFR mutation clearance can help to improve patient selection.

学科与关键词

关键词
TKINSCLCctDNAEGFROsimertinib
相关
加载中…
  • Circulating tumor DNA analysis of EGFR -mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment
    Jamie J. Beagan; Sander Bach; Robert A. van Boerdonk; Erik van Dijk; Erik Thunnissen; Daan van den Broek; Janneke Weiss; Geert Kazemier; D Michiel Pegtel; Idris Bahce; Bauke Ylstra; Daniëlle A.M. HeidemanLung Cancer, 2020, 145: 173-180.被引 6
  • Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients
    Eva Boysen Fynboe Ebert; Tine McCulloch; Karin Holmskov Hansen; Hanne Linnet; Boe Sorensen; Peter Meldgaard2020.
  • Serial plasma cell-free circulating tumor DNA tests identify genomic alterations for early prediction of osimertinib treatment outcome in EGFR T790M-positive non-small cell lung cancer
    Bin-Chi Liao; Wei-Hsun Hsu; Jih-Hsiang Lee; Ching-Yao Yang; Tzu-Hsiu Tsai; Wei-Yu Liao; Chao-Chi Ho; Chia-Chi Lin; Jin-Yuan Shih; Chong-Jen Yu; Ross A. Soo; James Chih-Hsin YangJTO Clinical and Research Reports, 2020, 100099.
查看全部 →

发表信息

论文状态
公开发表
期刊
European Journal of Cancer
发表日期
2021
卷期
第 149 卷
DOI
10.1016/J.EJCA.2021.02.031
成果收录
CHINAJOURNAL
资助标注
Medical Oncology; Hospital Universitario Puerta de Hierro Majadahonda; Majadahonda; Madrid; Spain;Biostatistics Unit; Hospital Universitario Puerta de Hierro- Majadahonda; CIBERESP; Majadahonda; Madrid; Spain;Medical Oncology; Hospital Provincial Centre de Castelló; Castellón de La Plana; Castellón; Spain;Medical Oncology; Hospital Universitario de Burgos; Burgos; Burgos; Spain;Medical Oncology; Fundación Jiménez Díaz; Madrid; Madrid; Spain;Medical Oncology; Hospital General Universitario Valencia; Valencia; Valencia; Spain;Medical Oncology; Hospital de La Princesa; Madrid; Madrid; Spain;Medical Oncology; Hospital Universitario de Canarias; La Laguna; Santa Cruz de Tenerife; Spain;Medical Oncology; Hospital ICO Girona; Girona; Girona; Spain;Medical Oncology; Hospital Basurto; Bilbao; Vizcaya; Spain;Medical Oncology; Hospital Universitario Infanta Sofía; San Sebastián de Los Reyes; Madrid; Spain;Medical Oncology; Consorcio Hospitalario de Jaén; Jaén; Jaén; Spain;Medical Oncology; Hospital Universitario de Guadalajara; Guadalajara; Guadalajara; Spain;Medical Oncology; Complejo Hospitalario de Navarra; Pamplona; Navarra; Spain;Medical Oncology; Hospital Universitario Nuestra Señora de Candelaria; Santa Cruz de Tenerife; Santa Cruz de Tenerife; Spain;Medical Oncology; Hospital Son Llàtzer; Palma; Islas Baleares; Spain;Medical Oncology; Consorci Sanitari Terrassa; Terrassa; Barcelona; Spain;Medical Oncology; Hospital General Universitario Santa Lucia; Cartagena; Murcia; Spain;Medical Oncology; Hospital Universitario Fundación Alcorcón; Alcorcón; Madrid; Spain;Medical Oncology; Hospital Universitario Infanta Cristina; Parla; Madrid; Spain;Mixed Unit TRIAL; Príncipe Felipe Research Center & General University Hospital of Valencia Research Foundation; Valencia; Spain;Laboratory of Oncology/Pangaea Oncology; Quirón-Dexeus University Hospital; Barc

作者

  • P

    Provencio Mariano (第一作者)

  • S

    Serna-Blasco Roberto

查看全部 28 位作者收起作者
  • F

    Franco Fabio

  • C

    Calvo Virgina

  • R

    Royuela Ana

  • A

    Auglytė Milda

  • S

    Sánchez-Hernández Alfredo

  • d

    de Julián Campayo María

  • G

    García-Girón Carlos

  • D

    Dómine Manuel

  • B

    Blasco Ana

  • S

    Sánchez José M.

  • O

    Oramas Juana

  • B

    Bosch-Barrera Joaquim

  • S

    Sala María Á.

  • S

    Sereno María

  • O

    Ortega Ana L.

  • C

    Chara Luis

  • H

    Hernández Berta

  • P

    Padilla Airam

  • C

    Coves Juan

  • B

    Blanco Remedios

  • B

    Balsalobre José

  • M

    Mielgo Xabier

  • B

    Bueno Coralia

  • J

    Jantus-Lewintre Eloisa

  • M

    Molina-Vila Miguel Á.

  • R

    Romero Atocha

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417